Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025
Micro‑cap biotech Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is back in the spotlight today after securing a new $100 million equity line of credit and releasing its Q3 2025 10‑Q, sending the stock sharply higher in pre‑market trading. ASBP stock